March 9 (Reuters) - Opthea Ltd OPT.AX :
* Anticipates reporting of outcomes from ongoing phase 2a dose expansion cohorts of clinical trial by end of March 2017
* Completes FDA meeting to inform opt-302 wet amd clinical program Source text for Eikon: Further company coverage: OPT.AX